CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

Core Insights - CytoSorbents Corporation will report its second quarter 2024 operating and financial results on August 13, 2024, after market close [1] - A live conference call and presentation will be held at 4:30 PM EDT on the same day [2] Company Overview - CytoSorbents Corporation specializes in treating life-threatening conditions in intensive care and cardiac surgery through blood purification [3] - The company's lead product, CytoSorb®, is an extracorporeal cytokine adsorber approved in the EU and distributed in 75 countries, designed to reduce cytokine storms in critical illnesses [3] - As of March 31, 2024, over 237,000 CytoSorb devices have been used cumulatively [3] Product Development - The investigational DrugSorb™-ATR system has received two FDA Breakthrough Device Designations for removing specific anticoagulants during cardiothoracic procedures [4] - The STAR-T study, involving 140 patients across approximately 30 centers in the U.S. and Canada, evaluated the safety and efficacy of DrugSorb-ATR [4] Funding and Technology - CytoSorbents has secured approximately $50 million in funding from various U.S. government agencies for its purification technologies [5] - The company holds numerous patents and has multiple products under development based on its blood purification technology [5]